MB Levis & Associates LLC Acquires 135 Shares of Johnson & Johnson $JNJ

MB Levis & Associates LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 11,676 shares of the company’s stock after buying an additional 135 shares during the quarter. Johnson & Johnson makes up approximately 0.8% of MB Levis & Associates LLC’s portfolio, making the stock its 24th largest holding. MB Levis & Associates LLC’s holdings in Johnson & Johnson were worth $1,783,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Apexium Financial LP increased its position in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after buying an additional 2,310 shares during the last quarter. Avanza Fonder AB grew its stake in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after acquiring an additional 6,566 shares during the period. Joel Isaacson & Co. LLC increased its holdings in Johnson & Johnson by 3.5% in the 1st quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock worth $12,294,000 after acquiring an additional 2,526 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in Johnson & Johnson by 7.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock valued at $12,164,000 after acquiring an additional 4,816 shares during the period. Finally, Absher Wealth Management LLC lifted its holdings in Johnson & Johnson by 1.2% during the first quarter. Absher Wealth Management LLC now owns 215,584 shares of the company’s stock valued at $35,752,000 after purchasing an additional 2,469 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 0.6%

Johnson & Johnson stock opened at $193.27 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.40. The stock has a market cap of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. The firm’s fifty day moving average price is $180.49 and its 200-day moving average price is $164.90.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. UBS Group lifted their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the company a “buy” rating in a research note on Tuesday, October 14th. Argus set a $210.00 target price on Johnson & Johnson in a research report on Wednesday. Raymond James Financial lifted their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, The Goldman Sachs Group increased their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $199.88.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.